PhytoGaia to launch a squalene-tocotrienol ingredient combo at SupplySide West
PhytoGaia calls STGaia “the first of its kind in the market.”
PhytoGaia (Staten Island, NY) will highlight its latest tocotrienol-based ingredients at the SupplySide West trade show, taking place October 31 to November 4, 2022, in Las Vegas (Booth #7325). One new ingredients is STGaia, a combination of squalene and tocotrienol complex.
PhytoGaia calls STGaia “the first of its kind in the market.” The company says, “STGaia is a new and novel synergistic combo of natural squalene and tocotrienol complex…specifically developed for oral and topical skin beauty (skin nutrition and antiaging).”
Squalene, derived from shark liver, is already a popular ingredient in topical cosmetic products. The combination with tocotrienols is especially beneficial, as tocotrienols have “significant” science demonstrating skin nutrition and antiaging properties, the firm says.
“While squalene and tocotrienols are used widely and individually in topical and oral cosmetic products, they are not in a natural synergistic combination yet,” the company’s press release states. “As such, STGaia is the first natural plant-based extract with these two synergistic phytonutrients together as a complex.”
PhytoGaia’s tocotrienols are extracted from sustainably sourced palm fruits without the use of solvents or chemicals. They are available in a variety of forms, including oil suspension, water-dispersible powder, and a self-emulsifying liquid suspension.
Kratom sees impressive sales growth despite its regulatory status and stigma
March 12th 2025Despite its controversy, kratom is a top-selling ingredient that consumers see value in. That said, brands need to work hard to demonstrate safety and quality of kratom products in the absence of legal regulatory status. Will kratom be able to overcome its stigma for even more growth and consumer acceptance?
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.
